冠状动脉疾病的新兴治疗和诊断策略：当前趋势与未来展望。

IF 3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Problems in Cardiology Pub Date : 2024-09-22 DOI:10.1016/j.cpcardiol.2024.102863

Suresh Saravanan , Natarajan Alangudi Palaniappan , Anthoniammal Panneerselvam , Thirunavukkarasu Palaniyandi , Suba Rajinikanth , Rajeshkumar Shanmugam , Mugip Rahaman Abdul Wahab

{"title":"冠状动脉疾病的新兴治疗和诊断策略：当前趋势与未来展望。","authors":"Suresh Saravanan , Natarajan Alangudi Palaniappan , Anthoniammal Panneerselvam , Thirunavukkarasu Palaniyandi , Suba Rajinikanth , Rajeshkumar Shanmugam , Mugip Rahaman Abdul Wahab","doi":"10.1016/j.cpcardiol.2024.102863","DOIUrl":null,"url":null,"abstract":"<div><div>Coronary vascular disease (CVD) is the general term used to cover conditions like narrowed blood vessels that may cause stroke or heart attack. Coronary artery disease (CAD) is one of the CVD and it is the most severe disease worldwide. The traditional treatment for CAD includes Coronary Artery Bypass Graft Surgery (CABG) and Percutaneous Coronary Intervention (PCI). The evolution of science and technology has led to advancement in the treatment of CAD. Nanoparticles are very suitable for the treatment of CAD by using it as a capsule for targeted drug delivery. Non-coding RNAs like si-RNA and mi-RNA are used as therapeutic agents due to their unique characteristics. In recent years, this si-RNA and miRNA usage in treating diseases has significantly increased. These are used as therapeutic agents for CAD treatment due to their properties like unique mode of action and regulation of gene expression. Another treatment for CAD is stem cells. These are used in CAD treatment because they improve blood supply to the areas where the blood vessels are narrowed down due to atherosclerosis and also, they promote cardiac cell regeneration. These RNA and stem cells are usually encapsulated with nanoparticles to avoid degradation. In this article let us discuss in detail about the treatments of CAD.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"49 12","pages":"Article 102863"},"PeriodicalIF":3.0000,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Emerging therapeutic and diagnostic strategies for coronary artery disease: Current trends and future perspectives\",\"authors\":\"Suresh Saravanan , Natarajan Alangudi Palaniappan , Anthoniammal Panneerselvam , Thirunavukkarasu Palaniyandi , Suba Rajinikanth , Rajeshkumar Shanmugam , Mugip Rahaman Abdul Wahab\",\"doi\":\"10.1016/j.cpcardiol.2024.102863\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Coronary vascular disease (CVD) is the general term used to cover conditions like narrowed blood vessels that may cause stroke or heart attack. Coronary artery disease (CAD) is one of the CVD and it is the most severe disease worldwide. The traditional treatment for CAD includes Coronary Artery Bypass Graft Surgery (CABG) and Percutaneous Coronary Intervention (PCI). The evolution of science and technology has led to advancement in the treatment of CAD. Nanoparticles are very suitable for the treatment of CAD by using it as a capsule for targeted drug delivery. Non-coding RNAs like si-RNA and mi-RNA are used as therapeutic agents due to their unique characteristics. In recent years, this si-RNA and miRNA usage in treating diseases has significantly increased. These are used as therapeutic agents for CAD treatment due to their properties like unique mode of action and regulation of gene expression. Another treatment for CAD is stem cells. These are used in CAD treatment because they improve blood supply to the areas where the blood vessels are narrowed down due to atherosclerosis and also, they promote cardiac cell regeneration. These RNA and stem cells are usually encapsulated with nanoparticles to avoid degradation. In this article let us discuss in detail about the treatments of CAD.</div></div>\",\"PeriodicalId\":51006,\"journal\":{\"name\":\"Current Problems in Cardiology\",\"volume\":\"49 12\",\"pages\":\"Article 102863\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Problems in Cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0146280624004985\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Problems in Cardiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0146280624004985","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

冠状动脉血管疾病（CVD）是指血管狭窄等可能导致中风或心脏病发作的疾病的总称。冠状动脉疾病（CAD）是 CVD 的一种，也是全球最严重的疾病。冠状动脉疾病的传统治疗方法包括冠状动脉旁路移植手术（CABG）和经皮冠状动脉介入治疗（PCI）。科学技术的发展推动了治疗冠状动脉粥样硬化的进步。纳米颗粒非常适合治疗冠状动脉粥样硬化，可用作靶向给药的胶囊。si-RNA 和 mi-RNA 等非编码 RNA 因其独特的特性而被用作治疗药物。近年来，si-RNA 和 miRNA 在治疗疾病方面的应用大幅增加。由于其独特的作用模式和基因表达调控等特性，它们被用作治疗 CAD 的治疗剂。另一种治疗 CAD 的方法是干细胞。干细胞可改善动脉粥样硬化导致的血管狭窄部位的血液供应，还能促进心脏细胞再生，因此被用于治疗 CAD。这些核糖核酸和干细胞通常用纳米颗粒封装，以避免降解。在这篇文章中，让我们详细讨论一下CAD的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Emerging therapeutic and diagnostic strategies for coronary artery disease: Current trends and future perspectives

Coronary vascular disease (CVD) is the general term used to cover conditions like narrowed blood vessels that may cause stroke or heart attack. Coronary artery disease (CAD) is one of the CVD and it is the most severe disease worldwide. The traditional treatment for CAD includes Coronary Artery Bypass Graft Surgery (CABG) and Percutaneous Coronary Intervention (PCI). The evolution of science and technology has led to advancement in the treatment of CAD. Nanoparticles are very suitable for the treatment of CAD by using it as a capsule for targeted drug delivery. Non-coding RNAs like si-RNA and mi-RNA are used as therapeutic agents due to their unique characteristics. In recent years, this si-RNA and miRNA usage in treating diseases has significantly increased. These are used as therapeutic agents for CAD treatment due to their properties like unique mode of action and regulation of gene expression. Another treatment for CAD is stem cells. These are used in CAD treatment because they improve blood supply to the areas where the blood vessels are narrowed down due to atherosclerosis and also, they promote cardiac cell regeneration. These RNA and stem cells are usually encapsulated with nanoparticles to avoid degradation. In this article let us discuss in detail about the treatments of CAD.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Problems in Cardiology 医学-心血管系统

CiteScore

4.80

自引率

2.40%

发文量

392

审稿时长

6 days

期刊介绍： Under the editorial leadership of noted cardiologist Dr. Hector O. Ventura, Current Problems in Cardiology provides focused, comprehensive coverage of important clinical topics in cardiology. Each monthly issues, addresses a selected clinical problem or condition, including pathophysiology, invasive and noninvasive diagnosis, drug therapy, surgical management, and rehabilitation; or explores the clinical applications of a diagnostic modality or a particular category of drugs. Critical commentary from the distinguished editorial board accompanies each monograph, providing readers with additional insights. An extensive bibliography in each issue saves hours of library research.